Calliditas Therapeutics AB
https://www.calliditas.se/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Calliditas Therapeutics AB
Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy
Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).
Novartis Aims To Dominate Rare Renal Disorders
Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.
First-To-Market Calliditas Picking Up Speed In IgA Nephropathy
A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.
Calliditas Confident Of Setanaxib's Potential Despite Unclear Data
The Sweden-headquartered biotech has emphasized the promising survival data in a head and neck cancer study of setanaxib rather than the NOX inhibitor’s inability to shrink tumors.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Pharmalink AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice